Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Recruiting

Phase 1

Phase 2

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic LeukemiaInotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Sponsor:

Leland Metheny

Code:

NCT03104491

Conditions

Acute Lymphocytic Leukemia

Eligibility Criteria

Sex: All

Age: 16 - 70+

Healthy Volunteers: Not accepted

Interventions

Inotuzumab Ozogamicin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-29. This information was provided to ClinicalTrials.gov by Leland Metheny on 2025-03-25.